Label-free ADAM10 capacitive assay for the early diagnosis of Alzheimer's disease
Loading...
External sources
External sources
Date
Advisor
Coadvisor
Graduate program
Undergraduate course
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Type
Article
Access right
Acesso aberto
External sources
External sources
Abstract
This study demonstrates a quantum capacitance-based approach using a peptide-redox-active interface modified with Ab1 and Ab2 ADAM10 isoform antibodies for the development of label-free and point-of-care assays that enable high-accuracy quantification of the target analyte in plasma samples. The sensitivity of the quantum capacitance to changes in interface energy upon analyte binding suggests significant potential for creating miniaturized diagnostic devices for non-communicable diseases, including Alzheimer's disease.
Description
Language
English
Citation
Sensors and Actuators B: Chemical, v. 427.
